WHO ICTRP trial
Efficacy and safety of Carfilzomib in combination with Ibrutinib vs. Ibrutinib…
CTIS2024-511929-60-00 · EU Clinical Trials Information System · Not Recruiting
Key facts
| Trial ID | CTIS2024-511929-60-00 |
|---|---|
| Public title | Efficacy and safety of Carfilzomib in combination with Ibrutinib vs. Ibrutinib alone in Waldenström’s Macroglobulinemia (CZAR-1) |
| Scientific title | Efficacy and safety of Carfilzomib in combination with Ibrutinib vs. Ibrutinib alone in Waldenström’s Macroglobulinemia (CZAR-1) - CZAR-1 |
| Primary sponsor | Universitaetsklinikum Ulm AöR |
| Registry | EU Clinical Trials Information System |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): No Therapeutic exploratory (Phase II): Yes Therapeutic confirmatory - (Phase III): No Therapeutic use - (Phase IV): No |
| Countries | Austria;Germany;Greece |
| Conditions | Waldenström’s Macroglobulinemia MedDRA version: 21.0Level: PTClassification code: 10047801Term: Waldenstrom's macroglobulinaemia Class: 100000004864;Therapeutic area: Diseases [C] - Neoplasms [C04];Therapeutic area: Diseases [C] - Hemic and… |
| Interventions | Product Name: Kyprolis 60 mg powder for solution for infusion, Product Code:PRD3374183, Pharmaceutical Form: SOLUTION FOR INFUSION, Other descriptive name: , Strength: , Product Name: IMBRUVICA 140 mg hard capsules, Product Code:PRD1729387… |
| Registration date | Jun 9, 2024 |
| Target size | 105 |
| Secondary IDs | NCT04263480;2018-003526-88 |
| Registry page | euclinicaltrials.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: